Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vistagen Therap. Com (VTGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart
Realtime quote and/or trade prices are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,998
  • Shares Outstanding, K 11,700
  • Annual Sales, $ 1,250 K
  • Annual Income, $ -10,260 K
  • 36-Month Beta -3.00
  • Price/Sales 8.56
  • Price/Cash Flow 0.00
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.47
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/13/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.75 +25.33%
on 11/14/17
1.63 -42.33%
on 10/26/17
-0.33 (-25.98%)
since 10/17/17
3-Month
0.75 +25.33%
on 11/14/17
1.94 -51.55%
on 08/18/17
-0.83 (-46.89%)
since 08/17/17
52-Week
0.75 +25.33%
on 11/14/17
4.08 -76.96%
on 12/05/16
-2.86 (-75.26%)
since 11/17/16

Most Recent Stories

More News
VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, CA--(Marketwired - November 09, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 0.94 (+3.30%)
VistaGen Therapeutics Reports Second Fiscal Quarter 2018 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, CA--(Marketwired - November 09, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 0.94 (+3.30%)
VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of Depression

SOUTH SAN FRANCISCO, CA--(Marketwired - November 06, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 0.94 (+3.30%)
VistaGen Therapeutics Receives European Patent for AV-101 for Treatment of Depression

SOUTH SAN FRANCISCO, CA--(Marketwired - November 06, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 0.94 (+3.30%)
VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder

SOUTH SAN FRANCISCO, CA--(Marketwired - October 26, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 0.94 (+3.30%)
VistaGen Announces FDA Authorization to Initiate Phase 2 Study of AV-101 for Major Depressive Disorder

SOUTH SAN FRANCISCO, CA--(Marketwired - October 26, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 0.94 (+3.30%)
VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent Regarding Methods of Production for AV-101

SOUTH SAN FRANCISCO, CA --(Marketwired - September 28, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 0.94 (+3.30%)
VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent Regarding Methods of Production for AV-101

SOUTH SAN FRANCISCO, CA --(Marketwired - September 28, 2017) - VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression...

VTGN : 0.94 (+3.30%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by VistaGen Therapeutics, Inc.

Levi & Korsinsky announces it has commenced an investigation of VistaGen Therapeutics, Inc. (NASDAQ: VTGN) concerning possible breaches of fiduciary duty. To obtain additional information,...

VTGN : 0.94 (+3.30%)
VistaGen Announces Closing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock

SOUTH SAN FRANCISCO, CA--(Marketwired - September 06, 2017) - VistaGen Therapeutics, Inc. (NASDAQ: VTGN) (VistaGen or the Company), a clinical-stage biopharmaceutical company focused on developing new...

VTGN : 0.94 (+3.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company's lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development,...

See More

Key Turning Points

2nd Resistance Point 1.03
1st Resistance Point 0.98
Last Price 0.94
1st Support Level 0.88
2nd Support Level 0.83

See More

52-Week High 4.08
Fibonacci 61.8% 2.81
Fibonacci 50% 2.41
Fibonacci 38.2% 2.02
Last Price 0.94
52-Week Low 0.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart